Food, Drugs, Healthcare, Life Sciences

2025 brought significant, fast-moving change to the U.S. Food and Drug Administration (FDA), and the organization has undergone extensive modifications as one component...

Just in time for the holidays, on December 15, 2025, the U.S. Food and Drug Administration ("FDA") Office of Prescription Drug Promotion ("OPDP") issued an untitled letter (the "Letter") to Karuna Therapeutics...

In December, the Centers for Medicare & Medicaid Services (CMS) proposed two new drug pricing models designed to address sustained growth in prescription drug spending across Medicare, driven in part by U.S. drug prices that remain substantially higher than prices paid in other developed countries.

For years, the government has been touting the importance of healthcare organizations having an "effective" healthcare compliance program.

In this Sidecar episode of our Committed Capital podcast, Markus Bolsinger, co-head of Dechert's global private equity practice, joins Dechert partner Jennifer Csik Hutchens and associate...

2025 brought significant, fast-moving change to the U.S. Food and Drug Administration (FDA), and the organization has undergone extensive modifications as one component...

On December 17, 2025, the U.S. Food and Drug Administration (FDA) issued a request for information (RFI) on a proposal designed to help the FDA engage more directly with innovative, venture-backed companies focused on biotechnology, medical devices, AI, and regulatory technology.

Spurred by ongoing allegations of fraud in the State of Minnesota, where federal investigators have alleged upwards of $9 billion...

The Centers for Medicare & Medicaid Services (CMS) Center for Medicare and Medicaid Innovation (CMMI) (Innovation Center) has unveiled a series of new models related to the administration's focus on improving the health of Americans with chronic illness and lowering drug pricing.